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Purpose: Despite extensive study, the use of allogeneic hematopoietic stem cell 
transplantation in acute myeloid leukemia (AML) vary considerably. The decision 
of which of these options to choose is complex and depends on both clinical and 
molecular variables as well as the availability and histocompatability of donor 
stem cells. So far there is no clear explanation on whether the expression of my-
eloperoxidase (MPO) relates to the prognosis of AML. Materials and Methods: 
We retrospectively analyzed the prognostic significance of the MPO expression in 
the 140 patients with diagnosed AML treated at a single institution. Results: In our 
study, MPO expression was associated with disease-free survival (DFS) and trans-
plant was beneficial to overcome a negative prognostic effect of MPO-negative at 
diagnosis based upon the result that the DFS in patients received transplants are 
not significant between the MPO-positive group and MPO-negative group al-
though DFS in all patients was different according to MPO expression. Conclu-
sion: MPO expression at diagnosis helps to choose therapy for each AML patient 
and can differentiate AML patients who need transplantation.
Key Words:    Myeloperoxidase, acute myeloid leukemia, prognostic factor, trans-
plant
INTRODUCTION
Most patients with newly diagnosed acute myeloid leukemia (AML) will achieve 
a first complete remission (CR1) with standard induction chemotherapy and re-
quire either further (post-remission) chemotherapy or allogeneic hematopoietic 
stem cell transplantation (alloHCT) for obtaining a durable remission. The deci-
sion of which of these options to choose is complex and depends on both clinical 
and molecular variables as well as the availability and histocompatability of donor 
stem cells.1
Although karyotype analysis provides a powerful independent prognostic factor 
for rates of CR, relapse rate and overall survival (OS) in multivariable analyses,2 
there are several limitations in the use of karyotype as a risk stratification tool; 
these include failed cytogenetic analyses, presence of cryptic chromosomal rear-
rangements and the fact that a substantial proportion of AML cases (-40%) have a Myeloperoxidase Expression in Acute Myeloid Leukemia
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currently in use in the different center. The reactivity with 
anti MPO, CD11c, CD13, CD14, CD15, CD33, CD65s and 
CD117, referred to as myeloid markers was analyzed. A 
case was considered to be positive for a marker if ≥20% of 
the blasts were positive according to EGIL guideline.10 In 
this analysis, we scored leukemias positive for anti-MPO if 
>50% of the blasts showed expression. 
Cytogenetic and molecular genetic analysis
Chromosome analysis was performed on metaphases from 
preparations of bone marrow samples. The cytogenetic prep-
aration and G-banding were carried out according to routine 
laboratory procedure.11 Chromosome was interpreted based 
on the International System for Human Cytogenetic Non-
menclature. Patients were classified into a favorable, inter-
mediate, or adverse risk group based on their karyotypes ac-
cording to the MRC AML 10 study published.2 Diagnostic 
samples were also analyzed for mutations in the fms-related 
tyrosine kinase 3 gene (FLT3) [i.e., the internal tandom du-
plications (ITDs) and tyrosine kinase domain mutations at 
codons D835 and I836]. 
Statistical analysis
Patient characteristics in cases with or without MPO ex-
pression by risk factors were compared using the χ2 test in 
case of discrete variables or using the t-test in case of con-
tinuous variables. OS was measures from diagnosis until 
death from any cause. Patients still alive at the date of last 
contact were censored at the last follow-up date. Disease-
free survival (DFS) was measured from achieving CR until 
relapse, death from any cause or last follow-up. If patients 
who were not in remission at the time of transplantation, 
DFS were measured from the time of transplantation. OS 
and DFS were estimated using the Kaplan-Meier method, 
and were compared by the log-rank test according to the 
MPO expression. Furthermore, the simultaneous effect of 
risk factors on OS and DFS were analyzed using Cox᾽s pro-
portional-hazard model. Statistical significance is represent-
ed by two-tailed p values. 
 
RESULTS
 
The 140 patients included 81 males and 59 females, with a 
median age of 51. Table 1 shows the patient's characteristics. 
Patients were categorized into two groups according to MPO 
expression; 86 patients (62%) with MPO+ and 54 patients 
normal karyotype.3
Myeloperoxidase (MPO) is the hallmark enzyme of the 
myeloid lineage. MPO can be detected by cytochemical 
staining, immunohistochemistry, or flow cytometry. The di-
agnosis of AML is easy if more than 3% of blast cells are 
confirmed to be cytochemically MPO positive.4 A few stud-
ies have previously shown the prognostic significance of 
MPO in AML.5-8 However, so far there is no clear explana-
tion on whether the expression of MPO relates to the prog-
nosis of AML. 
We retrospectively analyzed the prognostic significance 
of the MPO expression in the 140 patients with diagnosed 
AML treated at a single institution.
MATERIALS AND METHODS
　　　
Patients
Between January 2006 to August 2010, a retrospective anal-
ysis was on 140 patients with newly diagnosed AML (age 
15 years or older) treated at the division of hematology, the 
Yonsei university college of medicine. The diagnosis and 
classification of AML was determined according to the FAB 
classification.9 Patient with clinical de novo AML and sec-
ondary AML were eligible for this trial; however, patients 
with FAB AML types M0, M7 [always MPO-negative 
(MPO-)], or M3 [always 100% MPO-positive (MPO+)] 
were excluded.
The induction regimen for remission was comprised of 
idarubicin (12 mg/m2/day I.V. over 30 min on days 1-3) in 
combination with cytosine arabinoside (ara-C) (100 mg/m2/
day I.V. continuous infusion on days 1-7). After achieve-
ment of a CR, the options for post-remission treatment 
were broad and choice of therapy was determined by the 
prognostic factors at diagnosis and beyond, patient and 
physician biases. Fifty-five (39%) patients were treated 
with 2-4 course of post-remission chemotherapy that in-
cluded high-dose ara-C (3 g/m2 I.V. every 12 hr on day 1, 3, 
and 5) as consolidation. Thirty-seven (26%) patients who 
had an available donor, went through alloHCT after several 
course of post-remission chemotherapy. Nine (16%) were 
assigned to autologous HCT (autoHCT).
Immunophenotypic analysis
Flow cytometric analysis of bone marrow and/or the pe-
ripheral blood cells was performed with an extensive panel 
of monoclonal antibodies according to (national) protocols Yundeok Kim, et al.
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cytogenetic analysis reveals an abnormal karyotype. Inter-
mediate cytogenetics were relatively common occurring in 
62% of cases, and 28 patients were classified in the adverse 
risk group. MPO expression was associated with favorable 
cytogenetic risk group (p=0.015). Cytogenetically normal 
AML was identified in 80 patients (57%), FLT3-ITD was 
founded in 3 patients (7%) with MPO+ and 3 patients (11%) 
with MPO- group (p=0.676).
OS and DFS
In this analysis, the median follow-up for the both groups 
was 12.2 months (range, 0.1-54.1). By the univariate analy-
sis, the age was significant factors associated with OS and 
DFS (Table 4). The OS at 1 year were 48% in younger age 
(<60 years) while elderly (≥60 years) was dead within 1 
year after diagnosis (p<0.001). The OS was not related with 
MPO expression (p=0.208) (Fig. 1A). The DFS at 1 year 
(38%) with MPO-. There were no statistically significant dif-
ferences in age, sex, presenting white blood count (WBC)
type of AML (de novo/secondary), central nervous system 
involvement at presentation between the MPO+ and the 
MPO- groups. M1, M2, M4 and M6 were major FAB sub-
types in all the MPO groups.
Of the 140 patients who diagnosed AML, 46 (32%) had 
received transplants, including 37 patients who got alloHCT 
from a matched sibling (n=21), unrelated (n=16) donor and 
and 9 patients who got autoHCT (p=0.797) (Table 2). The 
remaining 94 patients included 55 who received induction 
and/or post-remission chemotherapy, 39 who received only 
palliative therapy because of poor performance status or ad-
vanced age. Table 3 shows the nature of treatment. 
Cytogenetic risk group
In approximately 60% of patients with AML, pre-treatment 
Table 1. Patient Characteristics
MPO+ MPO- p value
Number of patients (%)    86 (61.4)    54 (38.6)
Age, median (range) (yrs)       48 (15-81)       53 (20-79) 0.282
Age (yrs) 0.291
    <60 60 (69) 33 (61)
    ≥60 34 (30) 21 (38)
Sex  0.537
    Male 48 (56) 33 (61)
    Female 38 (44) 21 (39)
Type 0.937
    De novo 68 (79) 43 (80)
    Secondary 18 (21) 11 (20)
Previous hematologic disorder 0.683
    Yes 15 (17)   8 (15)
    No 71 (83) 46 (85)
CNS involvement at presentation 0.314
    Yes 1 (1) 2 (3)
    No 85 (99) 52 (96)
FAB subtype 0.081
    M1, M2, M4, M6 67 (80) 44 (82)
    M5 3 (4)   6 (11)
    Not interpretable 14 (16) 4 (7)
Cytogenetics 0.015
    Adverse 13 (15) 15 (28)
    Favorable 17 (20) 4 (7)
    Intermediate 53 (62) 34 (58)
    NA of failed 3 (3) 4 (7)
FLT3-ITD mutation 3 (7)   3 (11) 0.676
WBC at diagnosis (×10
9/L) 0.302
    <100 83 (97) 50 (93)
    ≥100 3 (3) 4 (7)
MPO, myloperoxidase; MPO+, MPO-positive; MPO-, MPO-negative; CNS, central nervous system; FAB, French-American-British; WBC, white blood count; 
FLT3, fms-related tyrosine kinase 3 gene; ITD, internal tandom duplication.Myeloperoxidase Expression in Acute Myeloid Leukemia
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95% confidence interval (CI), 0.06 to 0.997]. Fig. 2A pres-
ents OS and DFS in patients received transplant according 
to MPO expression. Within 46 patients performed trans-
plant, the median DFS in 28 patients with MPO+ was not 
significantly different from in 18 MPO- patients (17.5 
months vs. 6.8 months; p=0.289). The median OS in the 
MPO- group was relatively less than in the MPO+ group, 
between two age group (<60 vs. ≥60 years) were 34% and 
3%, respectively (p=0.019). Patients with MPO- group had 
an inferior DFS than in MPO+ group (1-year DFS; 26% vs. 
50%, p=0.027) (Fig. 1B). In the multivariate analysis, all 
factors were not significant for OS, but the MPO was asso-
ciated with better DFS (Table 5). Patients of MPO+ groups 
had a better DFS than MPO- groups [p=0.049; HR, 0.076; 
Table 2. Characteristics of Transplants
MPO+ MPO- p value
Number of patients with HCT   28  18
Status at transplant 0.585
    CR1  25 (89)  15 (83)
    CR2    1 (4)    1 (6)
    Others    2 (7)    2 (11)
Time to transplant, months (range)    6 (3.7-18.7) 5.7 (3.9-12.4) 0.300
HCT type 0.797
    Matched sibling  13 (46)    8 (44)
    Matched unrelated     7 (25)    6 (33)
    Mismatched (≥1-allele mismatched unrelated)    2 (7)    1 (6)
    Autologous    6 (22)    3 (17)
CD34+ cells infused, 10
6/kg, median, range 5.6 (0.7-17.2) 5.0 (2.3-14.7) 0.626
Stem cell source 0.216
    PB  28 (100)  17 (94)
    BM    0    1 (6)
Conditioning 0.818
    MA  13 (46)    9 (50)
    NMA  15 (54)    9 (50)
GVHD 0.720
    Acute (grade ≥II)    7 (25)    6 (33)
    Chronic                      12 (43)    4 (22)
MPO, myeloperoxidase; MPO+, MPO-positive; MPO-, MPO-negative; HCT, hematopoietic stem cell transplantation; CR1, first complete remission; CR2, 
second complete remission; PB, peripheral blood; BM, bone marrow; MA, myeloablative; NMA, non-myeloablative; GVHD, graft-versus-host disease.
Table 3. The Nature of Treatment
MPO+ MPO- p value
Induction and/or post-remission chemotherapy (%)    33 (38.4) 22 (40.7) 0.954
Palliative therapy (%) 25 (29) 14 (25.9)
Transplantation (%)
    Allogeneic    22 (25.6) 15 (27.8)
    Autologous 6 (7) 3 (5.6)
MPO, myeloperoxidase; MPO+, MPO-positive; MPO-, MPO-negative.
Table 4. Prognostic Factors by Univariate Analysis
Prognostic factors
OS DFS
p value p value
MPO+ vs. MPO-   0.208   0.027
Age: <60 vs. ≥60 yrs <0.001 <0.001
Type: De novo vs. Secondary   0.200   0.152
Chromosomal risk group   0.472   0.590
WBC at diagnosis: <100000 vs. 100000 (×10
9/L)   0.605   0.093
OS, overall survival; DFS, disease-free survival; MPO, myeloperoxidase; MPO+, MPO-positive; MPO-, MPO-negative; WBC, white blood count.Yundeok Kim, et al.
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other study of 46 patients with FAB M2 AML reported op-
posite results that a high proportion of MPO+ blasts before 
treatment may have constituted a significantly unfavorable 
prognostic factor.8 So far, the clinical prognostic value of 
MPO expression in AML has been controversial. In this 
study, we analyzed the prognostic significance of the MPO 
expression in 140 patients with diagnosed AML. 
The MPO expression was significantly associated with 
DFS in the overall group, similar to other studies.4-6 Previ-
ous report demonstrated that the groups by the MPO ex-
pression in the intermediate cytogenetic risk group showed 
a significant difference in DFS. The DFS rates at 4 years 
were also different (p<0.001).4 
Although our study included a limited number of cases, 
transplant demonstrated an important role in improving 
clinical outcomes in AML. There was a significant differ-
ence in DFS between the MPO+ group and MPO- group 
(p=0.027). However, among the patients received trans-
plants, the DFS in overall was not difference in both groups 
(p=0.289). This results represented that the DFS in the 
but not statistically significant (28.6 months vs. 18.2 
months; p=0.375). Also, in patients received an alloHCT 
(except autoHCT), DFS and OS in the MPO+ group were 
not statistically different from those in the MPO- group 
(Fig. 2B).
DISCUSSION
In this study, the DFS of the patients received transplants in 
the MPO+ group was equal with that in the MPO- group, 
although the DFS of the all patient in MPO+ group was su-
perior than that in MPO- group. Several studies in AML 
have examined the prognostic significance of the propor-
tion of MPO+ blast cells. An ECOG study investigated the 
relationship between MPO+ percentage of blast cells and 
therapeutic outcomes of 72 patients with AML (FAB M1).6 
Thirty-eight patients with low MPO (<50%) group showed 
a significantly lower CR (52.6%) than the 34 patients with 
high MPO (>50%) group (85.3%, p=0.003). However, an-
Table 5. Prognostic Factors by Multivariate Analysis
Prognostic factors
OS DFS
p value Hazard ratio p value Hazard ratio
MPO+ vs. MPO- 0.068 0.152 0.049 0.076
Age: <60 vs. ≥60 yrs 0.999 2.176 0.999 1.190
Type (De novo vs. Secondary) 0.369 3.776 0.999 3.268
chromosomal risk group 0.150 0.472 0.153 0.168
WBC at diagnosis: <100 vs. ≥100 (×10
9/L) 1.000 1.666 1.000 1.548
OS, overall survival; DFS, disease-free survival; MPO, myeloperoxidase; MPO+, MPO-positive; MPO-, MPO-negative; WBC, white blood count.
Fig. 1. (A) OS by MPO expression at diagnosis in AML patients. There were not significant difference of OS between MPO+ and MPO- 
groups (p=0.208). (B) EFS by MPO expression at diagnosis in AML patients. Patients with MPO- group had an inferior DFS than in MPO+ 
group (1-year DFS; 26% vs. 50%, p=0.027). OS, overall survival; MPO, myloperoxidase; MPO+, MPO-positive; MPO-, MPO-negative; AML, 
acute myeloid leukemia; DFS, disease-free survival.
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In conclusion, despite its retrospective study including 
heterogenous patients with AML and small number of pa-
tients, MPO expression was associated with DFS and trans-
plant was beneficial to overcome a negative prognostic ef-
fect of MPO- at diagnosis based upon the result that the 
DFS in patients received transplants are not significant be-
tween the MPO+ group and MPO- group although DFS in 
all patients was different according to MPO expression.
MPO expression at diagnosis in AML patients could be 
one of the indicators that help identification of patients who 
benefit from transplantation. 
MPO- group was inferior than MPO+ group, but negative 
prognostic effect was overcame by receiving transplants if 
suitable donor exist. Previous reports suggested that high re-
lapse rates in patients with AML have led to enthusiasm for 
the intensification of treatment by the use of high-dose 
chemoradiotherapy followed by ‘rescue’ using allogeneic 
stem cells.12-14 The most important limiting factor for HCT 
remains the high treatment-related mortality. The long-term 
mortality from established grade IV GVHD has not changed 
significantly over the past three decades. The decision to un-
dergo HCT depend on the prognostic factors at diagnosis.15
Fig. 2. (A) OS by MPO expression at diagnosis for AML patients received transplants. Among the patients received transplants. A similar 
difference of OS was observed (p=0.375). (B) DFS OS by MPO expression at diagnosis for AML patients received transplants. Among the 
patients received transplants. There were not significant difference between MPO+ and MPO- groups (p=0.289). (C) OS by MPO expres-
sion at diagnosis for AML patients not received transplants. There were not significant difference of OS between MPO+ and MPO- 
groups (p=0.398). (D) EFS by MPO expression at diagnosis for AML patients not received transplants were significant difference between 
two groups (p=0.012). OS, overall survival; MPO, myloperoxidase; MPO+, MPO-positive; MPO-, MPO-negative; AML, acute myeloid leuke-
mia; DFS, disease-free survival.
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